|
BTG PLC: PUBLICATION OF POSITIVE DATA FROM TRX4 TYPE 1 DIABETES STUDY
27 September 2006 - BTG
| BTG plc, the medical innovations company, notes that TolerRx, Inc., BTG’s licensee for the anti-CD3 technology, has announced publication of positive Phase II data on TRX4 (ChAglyCD3), showing that a six-day course of TRX4 therapy in patients with type 1 diabetes reduced the amount of insulin needed to control blood glucose levels for at least 18 months. |
BTG plc, the medical innovations company, notes that TolerRx, Inc., BTG’s licensee for the anti-CD3 technology, has announced publication of positive Phase II data on TRX4 (ChAglyCD3), showing that a six-day course of TRX4 therapy in patients with type 1 diabetes reduced the amount of insulin needed to control blood glucose levels for at least 18 months. Louise Makin, Chief Executive Officer of BTG, commented:
“This study suggests TRX4 could be a real step forward in the treatment of type 1 diabetes. We look forward to further progress by TolerRx in developing this novel therapy.” TRX4 is one of six pharmaceuticals commercialised by BTG that are currently under clinical development by BTG’s licensees. BTG has three other products undergoing clinical studies prior to commercialisation.
http://www.btgplc.com
About: BTG
BTG is an intellectual property and technology commercialisation company that operates internationally. BTG creates value by investing in intellectual property and technology development, and in early stage ventures. We realise value through technology licensing, patent assertion and sale of equity investments. Through a multidisciplinary approach, we apply intellectual property and commercial expertise, together with specialist skills in science and technology, to create major product opportunities in the health and high tech sectors. BTG has commercialised important innovations, including Magnetic Resonance Imaging, Multilevel Cell Memory, Campath (alemtuzumab), the first monoclonal antibody treatment for chronic lymphocytic leukaemia, and recombinant Factor IX blood clotting protein. BTG operates through wholly owned subsidiaries BTG International Ltd and BTG International Inc in the UK and USA, respectively. |
More News:
• For September 2006
• From BTG
• For Polymer OLED Devices
|
